# Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

> **NCT00253214** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 973 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00253214
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** 2002-07
- **Target enrollment:** 973 (ACTUAL)
- **Last updated:** 2011-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253214, "Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00253214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*